Vitrolife's press release of annual accounts 2002

VITROLIFE'S PRESS RELEASE OF ANNUAL ACCOUNTS 2002 ·Net total sales amounted to SEK 103.3 million (100.1). ·Revenues for core activities increased by 17.1% to a total of SEK 75.2 million (64.2). ·Gross profits increased by 22.2% to a total of SEK 49.4 million (40.4) ·Cost-cutting and restructuring programs burdened the results by SEK 89 million. ·The group's net loss totalled SEK -116.5 million (-37.4). This result was affected by SEK -69.4 million in items affecting comparability. ·Vitrolife divested its sales rights to Ophthalin(TM) and Fermathron(TM), as well as its manufacturing plant in Edinburgh, Scotland. ·The Food and Drug Administration approved Vitrolife's request to market new cell culture media for in-vitro fertilization (GIII series - Closer to Nature) based on recombinant albumin and hyaluronan. See the enclosed press release of annual accounts for 2002. Gothenburg, February 19, 2003. Vitrolife AB (Publ) For further information, please contact: CEO: Magnus Nilsson, tel. +46 31 721 80 61, +46 708 22 80 61 e-mail: Finacial manager and IR agent: Margareta Fischer, tel. +46 31 721 80 13, +46 708 22 80 13 e-mail: ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full year-end report The full year-end report

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 400 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.